Long-term efficacy and safety of oxycodone–naloxone prolonged release in geriatric patients with moderate-to-severe chronic noncancer pain: a 52-week open-label extension phase study

Fabio Guerriero1 Department of Internal Medicine and Medical Therapy, Section of Geriatrics, University of Pavia, Milan, Italy;2 Department of Geriatrics, Agency for Elderly People of Pavia, Santa Margherita Institute, Pavia, Milan, ItalyCorrespondence[email protected]

Anna Roberto3 Department of Oncology, Pain and Palliative Care Research Unit, IRCCS-Mario Negri Institute for Pharmacological Research, Milan, Italy

Maria Teresa Greco4 Unit of Medical Statistics, Biometry and Epidemiology GA Maccacaro, Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy

Carmelo Sgarlata1 Department of Internal Medicine and Medical Therapy, Section of Geriatrics, University of Pavia, Milan, Italy

Marco Rollone2 Department of Geriatrics, Agency for Elderly People of Pavia, Santa Margherita Institute, Pavia, Milan, Italy

Oscar Corli3 Department of Oncology, Pain and Palliative Care Research Unit, IRCCS-Mario Negri Institute for Pharmacological Research, Milan, Italy

Long-term efficacy and safety of oxycodone–naloxone prolonged release in geriatric patients with moderate-to-severe chronic noncancer pain: a 52-week open-label extension phase study

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Long-term efficacy and safety of oxycodone–naloxone prolonged release in geriatric patients with moderate-to-severe chronic noncancer pain: a 52-week open-label extension phase study

Reprints and Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date